Japan is often approached as a “partner market.” Find a distributor, sign a deal, and let them handle commercialization.

That model can work but it comes with a fundamental trade-off: you give up the customer.

For companies with strong assets and long-term ambition, there is a different path—one that is increasingly viable in Japan today: building your own local presence and engaging the market directly.

---

The Strategic Advantage: Owning the Customer Relationship

In Japan, relationships are not transactional—they are built over time, grounded in trust, consistency, and local relevance.

When you operate through a third party, you are one step removed from:

• Physicians and KOLs
• Hospital systems
• Payers and policy influencers
• Real-world patient experience

That distance matters.

Without direct engagement, you miss:

• Unfiltered market feedback on your product’s positioning and usage
• Early signals on competitive threats or shifting treatment patterns
• The ability to adapt your strategy in real time

Over time, this creates a structural disadvantage. You are not truly in the market—you are observing it through someone else’s lens.

---

From Product Revenue to Market Equity

A distributor can generate sales.

A subsidiary builds equity.

When you establish your own presence in Japan, you are not just commercializing a product—you are building:

• A recognized brand among healthcare professionals
• Direct credibility with regulators and payers
• A platform for future launches
• Institutional knowledge that compounds over time

This is particularly important in Japan, where continuity and reputation carry significant weight. The value of these assets often exceeds the near-term efficiency gained through outsourcing.

---

Control Drives Better Decisions

Operating directly gives you control over:

• Positioning and messaging in a highly nuanced market
• Pricing and market access strategy
• Medical engagement and evidence generation
• Lifecycle management and indication expansion

In a market with regular price revisions and evolving reimbursement dynamics, this control is not just beneficial—it is critical.

---

“Japan Is Too Difficult” — Less True Than It Used to Be

Historically, companies avoided direct entry due to perceived barriers:

• Talent constraints
• Regulatory complexity
• Cultural and language differences

These challenges still exist—but they are increasingly manageable:

• Japan is more open to foreign companies than ever before
• Experienced local talent is available, particularly for compelling products
• Regulatory pathways are more transparent with early engagement

In reality, many of the risks associated with building a subsidiary are execution challenges not structural barriers.

---

When a Direct Model Makes Sense

Building your own subsidiary is not for every company. It becomes compelling when:

• You have a differentiated or high-value asset
• Japan is a strategic, not opportunistic, market
• You are willing to invest with a multi-year horizon
• Customer insight and lifecycle control are critical to success

In these situations, the question is not “Can we afford to build?”
It is often “Can we afford not to?”

---

A More Flexible Reality: Start Direct, Scale Smart

Direct entry does not mean building everything at once.

Many successful companies:

• Establish a small, focused local team
• Hold key functions (strategy, KOL engagement, market access) internally
• Selectively outsource execution where needed

This approach allows you to own the customer relationship from day one, while scaling infrastructure over time.

---

The Bottom Line

Japan rewards companies that commit.

If you rely entirely on partners, you may gain speed—but you limit your visibility, control, and long-term upside.

If you build your own presence, you gain something far more valuable:

• Direct insight
• Strategic control
• Enduring market equity

In a market like Japan, those advantages compound and ultimately define who wins.

Choosing the right distributor is one of the most critical decisions for life sciences companies entering or expanding in a new market. Whether in pharmaceuticals, biopharmaceuticals, medical devices, or med-tech, the wrong partner can slow growth, damage your brand, or block market access entirely.

This guide offers practical tips for carrying out thorough due diligence when selecting a new distributor, as well as strategies for correcting course in existing partnerships when the initial diligence didn’t reveal key issues.

---

Part 1: Operational & Commercial Due Diligence for New Distributors

Effective due diligence goes far beyond reviewing financial statements. Assessing whether a distributor can actually sell your product requires a deep dive into operational, commercial, and strategic capabilities.

1. Sales Force Structure and Coverage

• Number of reps covering your product category.
• Geographic reach and account segmentation.
• Experience with similar products or therapeutic areas.

2. Track Record of Product Launches

• Historical success launching similar products.
• Time-to-market performance for previous launches.
• Ability to meet sales targets consistently.

3. Customer Access and Relationships

• Depth and quality of relationships with hospitals, clinics, labs, or pharmacies.
• Access to KOLs and decision-makers.
• Ability to navigate procurement or hospital approval processes.

4. Sales Processes and Metrics

• Pipeline management and CRM usage.
• Lead follow-up speed and frequency.
• Reporting cadence, accuracy, and transparency.

5. Marketing and Promotion Capabilities

• Preparedness to run product demos, webinars, or scientific events.
• Existing marketing collateral and ability to adapt it for your product.
• Budget allocation for promotional campaigns.

6. Team Expertise and Commitment

• Knowledge of your product’s therapeutic area.
• Training programs for sales reps.
• Incentive structures aligned with your growth objectives.

7. Operational Risk Assessment

• Ability to handle regulatory reporting, cold chain logistics (if applicable), and customer service.
• Past incidents of compliance failures, stock-outs, or logistical delays.

Tip: Conduct site visits and ride-alongs if possible. Observing the team in action often reveals insights that documents or interviews cannot.

---

Part 2: Fixing Existing Partnerships When Due Diligence Was Missed or Misleading

Even the most thorough diligence cannot guarantee perfect results. When actual performance falls short, companies can take several steps:

1. Audit and Assess Current Performance

• Conduct a competency audit: sales, marketing, reporting, regulatory compliance.
• Compare actual results with initial expectations and contractual KPIs.

2. Improve Visibility and Transparency

• Require more frequent and structured reporting.
• Request access to customer or sales data (where possible).
• Introduce dashboard tracking of key metrics.

3. Reset Expectations and Roles

• Define clear KPIs and responsibilities moving forward.
• Conduct workshops or training to align the distributor with your product strategy.

4. Provide Support

• Offer marketing, sales, or clinical support to help them succeed.
• Facilitate introductions to KOLs or hospital networks.

5. Plan for Exit or Transition if Needed

• Maintain the ability to replace or supplement the distributor if performance doesn’t improve.
• Include contingency clauses in agreements for future transitions.

Key Insight: It is much easier and cheaper to prevent issues upfront than to correct them later, but structured audits and incremental intervention can salvage underperforming relationships.

---

Key Takeaways

• Due diligence is multi-dimensional: Commercial, regulatory, financial, strategic, and operational aspects all matter.
• Standardized scoring systems help compare potential distributors objectively.
• Missed diligence isn’t a lost cause: Audit, support, reset expectations, and maintain exit options.
• Long-term foresight is critical: Changing distributors later is expensive and disruptive — plan and structure your agreements accordingly.

---

At Invision Japan, we help life sciences companies thoroughly vet new distributors and rescue underperforming partnerships in Japan. Whether you’re entering the market or correcting course, structured assessment and proactive management are the keys to sustained success.

Many global executives are told the same story when sales in Japan disappoint:
“Japan is a difficult market.”
“Customers here are conservative.”
“The regulations are too strict.”

While there is truth in each of these statements, they are often used as a shield. In reality, many good products fail in Japan not because of the market itself, but because of issues closer to home: the structure, incentives, and performance of the chosen distributor or partner.

---

The Market Isn’t Always the Problem

Japan is the world’s third-largest economy. Customers here buy new medical devices, pharmaceuticals, technologies, and industrial products every day. Competitors launch and succeed. If your product has proven demand elsewhere, it’s unlikely that Japan is uniquely resistant.

What’s far more common is:

• Distributor passivity – waiting for orders instead of creating demand.
• Overreliance on existing relationships – your partner only pushes products that already sell.
• Limited transparency – poor reporting hides weak performance until it’s too late.
• Excuse-driven culture – “the market isn’t ready” becomes the default explanation for inaction.

---

Common Failure Patterns

1. Early enthusiasm, fast fade.
   A Japanese distributor initially invests in the relationship, then quietly shifts focus back to their core products once the “newness” wears off.
2. Big name, little effort.
   Companies often feel secure signing with a well-known trading house or distributor. But size doesn’t guarantee commitment — your product may never be more than a line item in a catalog.
3. Blaming culture instead of strategy.
   Politeness masks underperformance. You hear reassurance in meetings, but no sales momentum in the field.

---

What This Means for You

If your product is struggling in Japan, don’t assume the market is the problem. Instead, ask:

• Is our distributor really investing in this product, or just holding the license?
• Are they providing real sales and market feedback, or just excuses?
• Do we have visibility into their pipeline, customer meetings, and promotional activity?
• Have we defined performance expectations — and what happens if they’re not met?

---

Fixing the Problem

Improving distributor performance in Japan isn’t easy — but it is possible. Options include:

• Resetting the relationship – with clearer expectations, KPIs, and accountability.
• Providing tools and support – sales training, marketing materials, or market data.
• Applying pressure – making it clear that underperformance will lead to change.
• Exploring alternatives – sometimes the right answer is to replace, not repair.

---

Final Thought

Good products fail in Japan not because of some mysterious barrier in the market, but because of misaligned partnerships, lack of transparency, and unaddressed distributor underperformance.

The market is there. The demand is there. The question is whether your partner is really opening the door — or standing in the way.

---

At Invision, we specialize in helping companies diagnose and fix partner challenges in Japan. If your product isn’t performing, it may not be the market — it may be your partner. And that can be fixed.